Prostate Cell News Volume 2.09 | Mar 11 2011

 Cell Therapy News is now on Facebook. Join us!

 Follow us on Twitter! @ProstateCell

Interested in recruiting talented individuals? Post your career opportunities in Prostate Cell News at no cost. Contact us at info@connexoncreative.com

Presentations at Leading Radiation Oncology Meeting Highlight Cyberknife Prostate Outcomes from Patients at More Than 40 Centers
Accuray Incorporated announced clinical findings using non-invasive CyberKnife® stereotactic body radiation therapy for the treatment of prostate cancer. [Press release from Accuray Inc. discussing research presented at the 54th Annual American Society for Radiation Oncology (ASTRO) Meeting, Boston] Press Release

LABORATORY RESEARCH

Highly Efficient Capture of Circulating Tumor Cells by Using Nanostructured Silicon Substrates with Integrated Chaotic Micromixers
A new technology was demonstrated to enrich circulating tumor cells with high efficiency by integrating an antibody-coated silicon nanopillar substrate with an overlaid polydimethylsiloxane microfluidic chaotic mixer. [Angew Chem Int Ed Engl]

PrLZ Protects Prostate Cancer Cells from Apoptosis Induced by Androgen Deprivation via the Activation of Stat3/Bcl-2 Pathway
In this study, scientists showed that PrLZ enhanced in vitro growth and colony formation of prostate cancer cells on androgen deprivation as well as tumorigenicity in castrated nude mice. [Cancer Res]

Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression
The goal of this study was to investigate alterations in androgen receptor (AR) expression arising in a cell-based model of prostate cancer progression driven by truncated AR isoform activity. [Cancer Res]

Large Scale Exploration of Gene-Gene Interactions in Prostate Cancer Using a Multi-Stage Genome-Wide Association Study
Researchers explored evidence of interaction between pairs of 13 known susceptibility loci and single nucleotide polymorphisms across the genome to generate hypotheses about the functionality of prostate cancer susceptibility regions. [Cancer Res]

Regulation of HMGA1 Expression by MicroRNA-296 Affects Prostate Cancer Growth and Invasion
In this study, investigators examined the functional relation between microRNA-296 and high-motility group AT-hook gene 1 (HMGA1) expression in several prostate cancer (PC) cell lines and a large PC cohort. [Clin Cancer Res]

Oct1 Regulates Cell Growth of LNCaP Cells and Is a Prognostic Factor for Prostate Cancer
In the present study, the contribution of octamer transcription factor 1 (Oct1) to prostate cancer development was examined. [Int J Cancer]

Absence of Scavenger Receptor A Promotes Dendritic Cell-Mediated Cross-Presentation of Cell-Associated Antigen and Antitumor Immune Response
Using OVA-expressing RM1 prostate tumor line, scientists show for the first time that scavenger receptor A absence greatly enhances dendritic cells-mediated cross-presentation of OVA antigen derived from dying RM1 cells. [Immunol Cell Biol]

CLINICAL RESEARCH

The Association Between Diffusion of the Surgical Robot and Radical Prostatectomy Rates
The objective of the study was to determine the relationship between surgical robot acquisition and changes in volume of radical prostatectomy at the regional and hospital levels. [Med Care]

α1-Adrenoceptor Activation Induces Phosphorylation of β2-Adrenoceptors in Human Prostate Tissue
The objective of the study was to test whether β1-adrenoceptor activation leads to phosphorylation of the β2-adrenoceptor in human prostate tissue. [BJU Int]

Visceral Obesity and Inflammation Markers in Relation to Serum Prostate Volume Biomarkers Among Apparently Healthy Men
The associations of adiponectin and waist–hip ratio strengthen the link between insulin resistance and visceral adiposity to prostate volume markers among apparently healthy Arab men. [Eur J Clin Invest]

Dendreon Expands Launch of PROVENGE
Dendreon Corporation announced that the U.S. Food and Drug Administration approved the remainder of its New Jersey manufacturing facility, allowing the company to significantly increase the availability of PROVENGE® (sipuleucel-T) to help meet the needs of patients with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. [Dendreon Corporation Press Release]

Adamis Pharmaceuticals Files IND for Product Candidate to Treat Prostate Cancer
Adamis Pharmaceuticals Corporation announced that it has recently submitted to the U.S. Food and Drug Administration an Investigational New Drug (IND) application for APC-100 to treat prostate cancer. [BusinessWire]

Rapid Results with City Hospital’s ‘One-Stop-Prostate-Clinic’
Men with suspected prostate cancer are benefiting from a new ‘One-Stop-Prostate Clinic’ to avoid unnecessary delays in diagnosis and treatment for patients at University Hospitals Coventry and Warwickshire NHS Trust. [University Hospitals Coventry and Warwickshire Press Release National Health Service (NHS) Trust]

Alamance Regional Cancer Center Offers New Immunotherapy for Prostate Cancer
Alamance Regional Medical Center is offering a brand new immunotherapy treatment for advanced prostate cancer. [Alamance Regional Medical Center Press Release]

Accuray to Acquire TomoTherapy
Accuray and TomoTherapy Incorporated announced that they have signed a definitive agreement under which Accuray will acquire TomoTherapy for $4.80 per share in cash and stock, or a total of approximately $277 million. [Accuray Incorporated Press Release]

OncoVista Innovative Therapies Outlines Business Strategy; “Company Is Moving Full-Speed Ahead,” Says CEO
OncoVista Innovative Therapies, Inc. reported in a letter to shareholders that it is moving forward on its business plan to develop targeted, safer and more efficacious cancer treatments with reduced or no toxicity. [OncoVista Innovative Therapies, Inc. Press Release]

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Molecular Diagnostics for Cancer Drug Development 
June 28-30, 2011
Boston, United States 

NEW Targeted Antibodies for Cancer 2011
August 10-11, 2011
London, United Kingdom 

NEW International Conference and Exhibition on Cancer Science & Therapy
August 15-17, 2011
Las Vegas, United States 

NEW National Cancer Research Institute Cancer Conference
November 6-9, 2011
Liverpool, United Kingdom

NEW 21st Asia Pacific Cancer Conference 2011
November 10-12, 2011
Kuala Lumpur, Malaysia

Visit our events page to see a complete list of events in the prostate cell community.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.